You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProBristol Myers Squibb (BMY)
2 stories published on BMY since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Bristol Myers Squibb (BMY) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Supreme Court Upholds Medicare Drug Price Negotiation, Dealing Setback to Bristol-Myers Squibb, Amgen, and AbbVie
Drug pricing / FDA / IRA · Medium influence · Long term
CMS Drug Price Rule May Target Subcutaneous Keytruda and Opdivo, Hitting Merck and Bristol Myers
Direct news · Medium influence · Long term
Direct news
The most recent stories naming BMY directly, across all of our coverage.
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved BMY, with the stories behind each.
Also monitored for BMY (no news in our coverage yet): FDA approvals & trial outcomes.
See the full picture
Sign up free to track BMY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track BMY for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.